Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced today that investigators enrolled the first patient in a study of its EsoGuard. Investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center enrolled the patient in a U.S. Department of Defense-funded study of the EsoGuard esophageal DNA test for at-risk patients with gastroesophageal reflux disease (GERD). Lucid Diagnostics […]
Pavmed
PAVmed completes first-in-human implantations of its intraosseous infusion system
PAVmed (Nasdaq:PAVM) announced today that it successfully completed the first human implants of its PortIO intraosseous infusion system. New York-based PAVmed designed its PortIO system with an implantable intraosseous vascular access device and insertion kit. Instead of a catheter located in a vein, the system has a short extension from the device inserted by a physician […]
Pavmed appoints Shaun O’Neil as chief operating officer
Pavmed (NSDQ:PAVM) this week appointed Shaun O’Neil as EVP and COO O’Neil has served as Pavmed’s chief commercial officer and executive VP of business development since joining the company in 2018. Through his new roles, he will be responsible for overseeing diverse corporate operations and commercial activities within Pavmed and its subsidiaries. He will serve […]
Pavmed acquires CapNostics and its esophageal cell collection device
Pavmed (NSDQ:PAVM) announced today that it has agreed to buy CapNostics. The company entered into a definitive membership interest purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina–based CapNostics, according to a news release. CapNostics manufactures the FDA-cleared and CE-marked EsophaCap non-endoscopic esophageal cell collection device used in pre-commercial clinical […]
Pavmed subsidiary Lucid Diagnostics files registration statement for IPO
Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced that Lucid publicly filed a registration statement related to a proposed initial public offering (IPO). The number of shares of common stock and the price range for the offering have not yet been determined, according to a news release. Lucid Diagnostics intends to list its common stock on the Nasdaq market […]
Lucid Diagnostics gains CE mark for esophageal device
Lucid Diagnostics has received the CE mark for its EsoCheck esophageal cell collection device, its parent company announced today. EsoCheck is an FDA-cleared, swallowable balloon capsule catheter that enables a clinician to sample surface cells from the esophagus in a less than five-minute, non-invasive office procedure. Lucid touts EsoCheck as the only such device capable of […]
PAVmed wins CE mark for carpal tunnel device
PAVmed (NSDQ: PAVM) today announced that it has received the CE mark for its CarpX minimally invasive carpal tunnel device. EU-based Notified Body TÜV Rhineland LGA Products GMBH issued CE certificate, effective May 24, 2021, the company noted. CarpX may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, […]
DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently
Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player. In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors. Martha details […]
PavMed to spin off subsidiary Lucid Diagnostics
Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics will spin off into a separate public company. In a news release, Pavmed said Lucid Diagnostics intends to spin off if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation. […]
Pavmed closes $12.4m offering
Pavmed (NSDQ:PAVM) announced last week that it closed a registered direct offering of common stock shares worth $12.4 million. New York-based Pavmed’s previously announced offering included 6 million shares of common stock at a price of $2.24 per share, priced at-the-market under Nasdaq rules, according to a news release. The company estimates that the net proceeds […]
Pavmed raises $7.8M
Pavmed (NSDQ:PAVM) filed an SEC Form D to confirm the sale of $7.75 million in an offering of debt and options/warrants to purchase other securities. In selling the $7.75 million, New York-based Pavmed reached its total offering amount in the new notice, which made its first sale on Aug. 5. Pavmed did not intend for the […]
